Stifel Upgrades Profound Medical to Buy, Raises Price Target to $12
Portfolio Pulse from Benzinga Newsdesk
Stifel analyst Rick Wise has upgraded Profound Medical (NASDAQ:PROF) from Hold to Buy and raised the price target from $9 to $12.
July 16, 2024 | 9:30 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Stifel analyst Rick Wise has upgraded Profound Medical from Hold to Buy and increased the price target from $9 to $12.
The upgrade from Hold to Buy and the increase in price target from $9 to $12 by a reputable analyst is likely to positively impact the stock price of Profound Medical in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100